CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 103 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q2 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $228,000 | +61.7% | 115,821 | +2.5% | 0.00% | – |
| Q4 2020 | $141,000 | -30.5% | 113,023 | 0.0% | 0.00% | – |
| Q3 2020 | $203,000 | -75.8% | 113,023 | +12.9% | 0.00% | -100.0% |
| Q2 2020 | $840,000 | +60.3% | 100,065 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $524,000 | +5.0% | 100,065 | +9.5% | 0.00% | 0.0% |
| Q4 2019 | $499,000 | +12.1% | 91,392 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $445,000 | -29.7% | 91,392 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $633,000 | +7.5% | 91,392 | +7.9% | 0.00% | 0.0% |
| Q1 2019 | $589,000 | +29.7% | 84,711 | +9.0% | 0.00% | 0.0% |
| Q4 2018 | $454,000 | -21.2% | 77,739 | +1.8% | 0.00% | 0.0% |
| Q3 2018 | $576,000 | +49.2% | 76,342 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $386,000 | -15.4% | 76,342 | +2.1% | 0.00% | 0.0% |
| Q1 2018 | $456,000 | -15.9% | 74,799 | -2.1% | 0.00% | 0.0% |
| Q4 2017 | $542,000 | +5.7% | 76,403 | +6.5% | 0.00% | 0.0% |
| Q3 2017 | $513,000 | +3.6% | 71,729 | -8.6% | 0.00% | 0.0% |
| Q2 2017 | $495,000 | – | 78,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 397,168 | $43,888 | 0.01% |
| CJM Wealth Advisers, Ltd. | 30,465 | $3,366 | 0.00% |
| Tekla Capital Management LLC | 154,310 | $17,051 | 0.00% |
| McAdam, LLC | 10,006 | $6 | 0.00% |
| Aries Wealth Management | 15,400 | $1,702 | 0.00% |
| WELLS FARGO & COMPANY/MN | 342,084 | $37,800 | 0.00% |
| JPMORGAN CHASE & CO | 43,415 | $5 | 0.00% |
| NORTHERN TRUST CORP | 207,329 | $22,910 | 0.00% |
| PINNACLE ASSOCIATES LTD | 18,580 | $2,053 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |